ethinylestradiol-3-sulfate has been researched along with estramustine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fiedler, R; Klebingat, KJ; Lorenz, G; Panzig, E; Steinhauser, I | 1 |
| Miyazawa, Y; Nakano, K; Nakata, S; Sasaki, Y; Takahashi, H | 1 |
1 trial(s) available for ethinylestradiol-3-sulfate and estramustine
| Article | Year |
|---|---|
[Cellular immunity in prostatic cancer modified by Cytonal, Estrazyt and Turisteron].
Topics: Aged; Antineoplastic Agents; Clinical Trials as Topic; Combined Modality Therapy; Diethylstilbestrol; Estramustine; Ethinyl Estradiol; Humans; Immunity, Cellular; Macrophages; Male; Middle Aged; Nitrogen Mustard Compounds; Prostatic Neoplasms; Random Allocation | 1987 |
1 other study(ies) available for ethinylestradiol-3-sulfate and estramustine
| Article | Year |
|---|---|
[Prognostic factors for estrogen therapy of relapsed prostate cancer after maximal androgen blockade (MAB)].
Topics: Aged; Androgen Antagonists; Combined Modality Therapy; Diethylstilbestrol; Drug Therapy, Combination; Estramustine; Estrogens; Ethinyl Estradiol; Humans; Kaplan-Meier Estimate; Male; Neoplasm Recurrence, Local; Prognosis; Proportional Hazards Models; Prostatic Neoplasms; Survival Rate; Time Factors | 2010 |